Q2 Earnings Forecast for SRPT Issued By Zacks Research

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Equities researchers at Zacks Research issued their Q2 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a research report issued on Monday, May 26th. Zacks Research analyst S. Ganoria expects that the biotechnology company will post earnings of ($0.41) per share for the quarter. The consensus estimate for Sarepta Therapeutics' current full-year earnings is $2.67 per share. Zacks Research also issued estimates for Sarepta Therapeutics' Q3 2025 earnings at $0.23 EPS, Q4 2025 earnings at $0.25 EPS, FY2025 earnings at ($3.70) EPS, Q1 2026 earnings at $1.27 EPS, Q2 2026 earnings at $1.49 EPS, Q3 2026 earnings at $1.71 EPS, Q4 2026 earnings at $1.45 EPS, FY2026 earnings at $5.91 EPS, Q1 2027 earnings at $1.73 EPS and FY2027 earnings at $7.53 EPS.

Several other analysts also recently weighed in on the company. Morgan Stanley lowered their price objective on Sarepta Therapeutics from $182.00 to $113.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. HC Wainwright reiterated a "neutral" rating and issued a $40.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft reduced their target price on Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating on the stock in a research note on Wednesday, March 19th. Wells Fargo & Company reduced their target price on Sarepta Therapeutics from $115.00 to $100.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Finally, Oppenheimer reduced their target price on Sarepta Therapeutics from $184.00 to $123.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has an average rating of "Moderate Buy" and an average price target of $122.61.

Sarepta Therapeutics Trading Down 2.3%

SRPT stock traded down $0.89 during midday trading on Thursday, hitting $37.72. The company had a trading volume of 3,085,574 shares, compared to its average volume of 1,795,450. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a 52 week low of $34.10 and a 52 week high of $173.25. The stock's 50 day moving average price is $50.84 and its 200 day moving average price is $91.78. The stock has a market cap of $3.71 billion, a price-to-earnings ratio of 30.18 and a beta of 0.85.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts' consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter in the previous year, the firm earned $0.73 EPS. The business's quarterly revenue was up 80.2% compared to the same quarter last year.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Louisiana State Employees Retirement System increased its position in Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company's stock worth $3,222,000 after buying an additional 100 shares in the last quarter. EP Wealth Advisors LLC increased its position in Sarepta Therapeutics by 2.2% in the fourth quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company's stock worth $606,000 after buying an additional 105 shares in the last quarter. Manchester Capital Management LLC increased its position in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after buying an additional 110 shares in the last quarter. CIBC Asset Management Inc increased its position in Sarepta Therapeutics by 5.1% in the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company's stock worth $347,000 after buying an additional 139 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Sarepta Therapeutics by 5.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company's stock worth $352,000 after buying an additional 145 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at $2,771,187.68. This represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 7.70% of the stock is owned by corporate insiders.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.